Lynpraza® (Olaparib) — PARP Inhibitor for BRCA-Mutated Cancers

Targeted PARP Inhibition for BRCA1/2 Mutation-Positive Cancers

Lynpraza® (Olaparib) is a poly ADP-ribose polymerase (PARP) inhibitor used to treat cancers with BRCA1 or BRCA2 mutations including ovarian, breast, pancreatic, and prostate cancer. Lynpraza contains the same active ingredient as Bracanat — Olaparib — and works through the same synthetic lethality mechanism that selectively targets BRCA-mutated cancer cells.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Lynpraza (Olaparib) to hospitals, oncology centres, clinics, and pharmacies across India. Manufactured by AstraZeneca in partnership with Merck (MSD), Lynpraza is one of the most important targeted cancer therapies available for BRCA-mutated malignancies.

What is Lynpraza (Olaparib)?

Lynpraza contains Olaparib, a first-in-class oral PARP inhibitor that exploits a concept known as synthetic lethality. Cancer cells with BRCA1 or BRCA2 mutations have defective homologous recombination repair (HRR) — they cannot effectively repair double-strand DNA breaks. By inhibiting PARP enzymes that repair single-strand DNA breaks, Lynpraza creates overwhelming DNA damage in BRCA-mutated cancer cells that they cannot repair, leading to selective cancer cell death.

This targeted mechanism makes Lynpraza highly selective for BRCA-mutated cancer cells while having a relatively lower impact on normal cells — the hallmark of precision oncology.

Full prescribing information is available at the FDA label for Olaparib.

Clinical Studies and Evidence

Lynpraza contains the same active ingredient as the originator brand Olaparib and shares the same extensive Phase 3 clinical evidence base.

SOLO-1 Trial (Olaparib Maintenance in Newly Diagnosed BRCA-Mutated Ovarian Cancer) Published in the New England Journal of Medicine (2018), the SOLO-1 trial demonstrated Olaparib maintenance therapy reduced the risk of disease progression or death by 70% at 3 years compared to placebo in patients with newly diagnosed advanced BRCA-mutated ovarian cancer following platinum-based chemotherapy.

SOLO-2 Trial (Olaparib Maintenance in Relapsed BRCA-Mutated Ovarian Cancer) Published in Lancet Oncology (2017), the SOLO-2 trial showed Olaparib maintenance significantly improved PFS with a median of 19.1 months vs 5.5 months for placebo in relapsed BRCA-mutated ovarian cancer.

OlympiAD Trial (Olaparib for BRCA-Mutated Breast Cancer) Published in the New England Journal of Medicine (2017), the OlympiAD trial demonstrated Olaparib significantly improved PFS compared to standard chemotherapy in BRCA1/2-mutated HER2-negative metastatic breast cancer.

OlympiA Trial (Adjuvant Olaparib in Early Breast Cancer) Published in the New England Journal of Medicine (2021), the OlympiA trial showed adjuvant Olaparib significantly improved invasive disease-free survival in patients with germline BRCA-mutated HER2-negative high-risk early breast cancer — establishing a new standard of care in the adjuvant setting.

POLO Trial (Olaparib for BRCA-Mutated Pancreatic Cancer) Published in the New England Journal of Medicine (2019), the POLO trial demonstrated Olaparib maintenance significantly improved PFS in germline BRCA-mutated metastatic pancreatic cancer patients who had not progressed on platinum-based chemotherapy.

PROfound Trial (Olaparib for HRR-Mutated Prostate Cancer) Published in the New England Journal of Medicine (2020), the PROfound trial showed Olaparib significantly improved radiographic PFS in HRR gene-mutated metastatic castration-resistant prostate cancer after progression on enzalutamide or abiraterone.

Available Strengths

Lynpraza is available in the following strengths:

• 100mg Film-coated Tablets
• 150mg Film-coated Tablets

The recommended dose is 300mg (two 150mg tablets) twice daily — total daily dose 600mg. Treatment continues until disease progression or unacceptable toxicity.

Indications — What Lynpraza is Used For

Ovarian Cancer

• Maintenance treatment of adults with BRCA1/2-mutated advanced ovarian cancer in complete or partial response to first-line platinum-based chemotherapy
• Maintenance treatment of platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer in response to platinum-based chemotherapy

Breast Cancer

• Treatment of adults with germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer previously treated with chemotherapy
• Adjuvant treatment of adults with germline BRCA1/2-mutated HER2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy

Pancreatic Cancer

• Maintenance treatment of adults with germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma not progressed on first-line platinum-based chemotherapy

Prostate Cancer

• Treatment of adults with BRCA1/2-mutated or HRR gene-mutated metastatic castration-resistant prostate cancer who progressed following prior enzalutamide or abiraterone treatment

For detailed indication information refer to NCI Olaparib Drug Information.

Key Benefits of Lynpraza

Same Proven Olaparib Efficacy Lynpraza contains the same Olaparib active ingredient as the originator brand with the same mechanism of action, efficacy, and safety profile across all approved indications.

Broad Cancer Coverage Approved across four different cancer types — ovarian, breast, pancreatic, and prostate — making it one of the most versatile targeted cancer therapies available in India.

Oral Twice Daily Administration Convenient oral tablets taken twice daily at home — eliminating the need for IV infusions and maintaining patient quality of life.

Fixed Duration Maintenance Option Available as maintenance therapy after platinum-based chemotherapy in ovarian cancer — helping to prolong the response achieved with initial treatment.

Proven Across Multiple Lines of Therapy Demonstrated efficacy in both first-line maintenance and relapsed/refractory settings across multiple tumour types.

Accessible Option Lynpraza provides an accessible Olaparib option for patients requiring PARP inhibitor therapy across India.

How Lynpraza Works

Lynpraza works through the synthetic lethality principle:

Normal cells have multiple DNA repair pathways including:

• Homologous Recombination Repair (HRR) — repairs double-strand DNA breaks (requires functional BRCA1/2)
• Base Excision Repair (BER) — repairs single-strand DNA breaks (requires PARP)

In BRCA-mutated cancer cells:

• HRR is defective — cancer cells cannot repair double-strand breaks effectively
• Cancer cells rely heavily on PARP-mediated BER to survive

Lynpraza works by:

• Inhibiting PARP1 and PARP2 enzymes that repair single-strand DNA breaks
• Trapping PARP proteins on damaged DNA creating toxic PARP-DNA complexes
• Causing replication fork collapse when trapped PARP complexes are encountered
• Creating lethal double-strand DNA breaks that BRCA-mutated cells cannot repair
• Selectively killing BRCA-mutated cancer cells through synthetic lethality

This mechanism is described in detail at Cancer Research UK — PARP Inhibitors.

Lynpraza vs Bracanat — Comparison

BRCA Testing Before Treatment

BRCA mutation testing is required before initiating Lynpraza therapy:

• Germline testing — blood or saliva test for inherited BRCA mutations (required for breast, pancreatic, and prostate cancer indications)
• Somatic testing — tumour tissue test for acquired BRCA mutations (may be used for ovarian cancer indications)

Testing should be performed using an FDA-approved or validated companion diagnostic test before initiating treatment.

Dosage and Administration

• Recommended Dose: 300mg (two 150mg tablets) twice daily — total daily dose 600mg
• Timing: Approximately 12 hours apart — morning and evening
• Administration: Orally with or without food
• Dose Reduction: 250mg twice daily then 200mg twice daily for adverse reactions
• Duration: Until disease progression or unacceptable toxicity
• Tablets: Swallow whole — do not crush, dissolve, or chew

Full dosing guidelines available at Drugs.com Olaparib Dosage.

Who Should Use Lynpraza

Lynpraza is prescribed for:

• Adults with BRCA1/2-mutated ovarian, breast, pancreatic, or prostate cancer meeting specific approved indications
• Patients confirmed to have BRCA or HRR gene mutations by validated testing
• Patients whose oncologist has determined they meet criteria for PARP inhibitor therapy

Lynpraza is prescribed by oncologists, gynaecological oncologists, breast oncologists, and urological oncologists. A.K. Pharma supplies Lynpraza to oncology centres, hospitals, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include nausea, fatigue, anaemia, vomiting, diarrhoea, decreased appetite, headache, neutropenia, thrombocytopenia, and abdominal pain.

Serious side effects include:

• Myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML) — discontinue if confirmed
• Pneumonitis — discontinue if confirmed
• Severe anaemia, neutropenia, or thrombocytopenia
• Venous thromboembolism

Full side effect information available at FDA Olaparib Safety Information.

Precautions

• BRCA mutation testing required before initiating therapy
• Monitor complete blood count at baseline and monthly for the first 12 months
• Discontinue if MDS or AML is confirmed
• Avoid strong or moderate CYP3A inhibitors — if unavoidable reduce Olaparib dose accordingly
• Avoid strong or moderate CYP3A inducers
• Effective contraception required during treatment and for 6 months after last dose for women
• Male patients should use effective contraception during treatment and for 3 months after

Storage and Handling

• Store at room temperature below 30°C
• Keep in original packaging — protect from moisture
• Keep out of reach of children
• Do not crush or chew tablets

As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Lynpraza under manufacturer-recommended conditions ensuring product integrity for every supply.

Manufacturer Information

Lynpraza (Olaparib) is manufactured by AstraZeneca in partnership with Merck (MSD). Olaparib received initial FDA approval in December 2014 as the first PARP inhibitor approved for cancer. A.K. Pharma supplies only genuine Lynpraza sourced from authorized distributors.

Related Cancer Medicines Available at A.K. Pharma

• Bracanat (Olaparib) — alternative brand of Olaparib available at A.K. Pharma
• Venclexta (Venetoclax) — BCL-2 inhibitor for blood cancers
• Faslodex (Fulvestrant) — hormone therapy for breast cancer
• Arimidex (Anastrozole) — aromatase inhibitor for breast cancer
• Kryxana (Ribociclib) — CDK4/6 inhibitor for breast cancer
• Palbace (Palbociclib) — CDK4/6 inhibitor for breast cancer
• Browse all Cancer Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Lynpraza used for? Lynpraza (Olaparib) is used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. More information available at Cancer.gov.

Q. What is the generic name of Lynpraza? The generic name of Lynpraza is Olaparib. It belongs to the PARP inhibitor class of targeted cancer therapies.

Q. What is the difference between Lynpraza and Bracanat? Both Lynpraza and Bracanat contain the same active ingredient Olaparib and have identical indications, mechanism, efficacy, and safety profiles. They are different brand names of the same medicine. A.K. Pharma supplies both — contact us for current availability and pricing.

Q. Is BRCA testing required before starting Lynpraza? Yes. BRCA mutation testing is required before initiating Lynpraza therapy. Testing can be performed on tumour tissue or blood depending on the specific cancer type and indication.

Q. Is Lynpraza available in India? Lynpraza can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Lynpraza in India? Lynpraza price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Lynpraza from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Lynpraza in bulk? Yes. A.K. Pharma supplies Lynpraza in bulk to oncology centres, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Lynpraza from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Lynpraza sourced from authorized AstraZeneca distributors
• Reliable supply to oncology centres, hospitals, and pharmacies across India
• Bulk supply available with competitive pricing
• Prompt response to all quote requests
• Serving oncologists across Delhi NCR and all major cities in India

Contact A.K. Pharma for Lynpraza Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in